> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sclerotic’ FDA ‘Shuns Innovation’: Column
- URL: https://www.fdaweb.com/sclerotic-fda-shuns-innovation-column/
- Published: 2026-01-14T12:00:00.000Z
- Updated: 2026-09-14T15:30:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160487

Taxpayers Protection Alliance executive director **Ross Marchand** uses a *Baltimore Sun* op-ed column to complain that FDA “has lost its way and shuns innovation.” He writes that as a result, “frustrated Americans are increasingly rebelling against the sclerotic agency by turning to gray and black markets for unproven ‘Chinese peptides’ and other drugs.”

While FDA commissioner **Marty Makary**’s list of 2025 accomplishments touted reducing decision times, hitting drug target date goals, accelerating cures, cutting red tape, and ushering in a new era of innovation, Marchand writes, Makary can only succeed in accelerating cures by boosting agency approvals and greenlighting lifesaving new medications, which he says can be done without compromising safety.

The op-ed contains several examples of the FDA approach to drugs that Marchand says show how bad the agency’s risk aversion has become.

He concludes that “FDA can save and improve countless lives by truly ‘accelerating cures’ and ‘cutting red tape.’ The current approach just isn’t working for millions of Americans suffering from treatable diseases.”